Ambrosia Biosciences Raises $100M Series B to Advance Oral Small-Molecule Therapies for Obesity
Ambrosia Biosciences didn’t arrive quietly. It walked into Boulder carrying unfinished business. When Pfizer shut down its Boulder R&D site, most saw an ending. Nick Traggis saw inventory. Not equipment…talent. The kind of medicinal chemistry firepower you don’t just recreate with a job post and a signing bonus. Now that same nucleus is back in motion, and the market just leaned in.
Ambrosia Biosciences pulled in $25M in Series A funding, with BVF Partners and Boulder Ventures leading the first close, and Merck stepping in to lead the second. That’s not just capital. That’s conviction from players who’ve seen enough science projects to know the difference between a maybe and a molecule with teeth. Let’s talk about what they’re actually building, because this isn’t another me-too biotech headline dressed in recycled language.
Ambrosia Biosciences is going after obesity and metabolic disorders with orally delivered small molecule therapies. Translation: they’re chasing the same biological pathways that made GLP-1 drugs a household name, but without the needle. Same conversation, different delivery. And if you understand patient behavior, you already know why that matters. An injection asks for commitment. A pill asks for consistency. That subtle shift? Market moving in ways most won’t fully appreciate until it’s already priced in.
The real play here isn’t just convenience. It’s scalability. Manufacturing, distribution, patient adoption. Small molecules have a history of moving faster, reaching further, and costing less to produce at scale. If Ambrosia Biosciences lands even part of this, the ripple effects won’t stay in Boulder. And here’s the part founders should sit with for a minute.
This round didn’t come from a flashy origin story or a viral moment. It came from assembling proven operators, anchoring in real science, and picking a fight in a market big enough to matter but specific enough to win. No theatrics. Just receipts. Merck doesn’t write checks because the deck looked pretty. BVF Partners and Boulder Ventures didn’t lead because the narrative sounded good on LinkedIn. This got done because the team, the timing, and the thesis lined up clean.
So yeah, congratulations to Nick Traggis and the Ambrosia Biosciences team. You didn’t just raise capital. You revived a lineage of drug discovery in Boulder and pointed it straight at one of the most commercially and clinically important problems on the planet. Some people inherit momentum. Others build it out of what everyone else left behind. This one feels like the second kind.
